Valiant Organics Grants 19,500 Employee Stock Options Under ESOP Scheme 2022

2 min read     Updated on 18 May 2026, 09:17 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Valiant Organics Limited's NRC approved the grant of 19,500 employee stock options under ESOP Scheme 2022 on May 16, 2026, at an exercise price of Rs. 10/- per option. Of the total, 15,000 options vest after a minimum period of 1 year, with the remainder subject to performance criteria. The scheme complies with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, and was disclosed under Regulation 30 of SEBI LODR Regulations, 2015.

powered bylight_fuzz_icon
40491779

*this image is generated using AI for illustrative purposes only.

Valiant Organics Limited's Nomination and Remuneration Committee (NRC) of the Board of Directors convened on Saturday, May 16, 2026, and approved the grant of 19,500 (Nineteen Thousand Five Hundred) employee stock options to eligible employees under the Valiant Employees Stock Option Plan 2022 ("ESOP Scheme"). The grant has been made in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company disclosed this development to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Details of the ESOP Grant

The following table summarises the key parameters of the stock option grant as disclosed in Annexure-I filed with the exchanges:

Parameter: Details
Total Options Granted: 19,500
Total Equity Shares Covered: 19,500
Exercise Price: Rs. 10/- per option
Face Value per Share: Rs. 10/- each
Conversion Ratio: 1 option = 1 equity share
Exercise Period: Within 3 years from date of vesting
Options Exercised: Nil
Options Lapsed: Nil
Money Realised by Exercise: Nil

Vesting Structure

The 19,500 options granted carry a structured vesting schedule as determined by the NRC. Of the total options granted, 15,000 options shall vest upon completion of a minimum vesting period of 1 year. The remaining options are subject to vesting upon achievement of specified performance criteria, as determined by the NRC in accordance with the applicable ESOP Scheme.

Once vested, each option entitles the holder to acquire one equity share of Valiant Organics upon payment of the exercise price. The exercise price shall in no event be less than the face value of the share, as prescribed under the scheme terms.

Scheme Administration and Compliance

The ESOP Scheme is administered by the NRC of the Board of Directors. The grant of options is based on eligibility criteria as defined under the scheme. The NRC determines the exercise price subject to conformity with applicable accounting policies. The scheme is in terms of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Key highlights of the scheme's governance framework include:

  • The NRC oversees administration and eligibility determination
  • Exercise price is set at Rs. 10/- per option, consistent with the face value
  • Diluted earnings per share pursuant to the issue of equity shares on exercise of options is not yet applicable, as options are yet to be exercised
  • No subsequent changes, cancellations, or variations to option terms have been reported

The intimation was signed by Kaustubh Kulkarni, Company Secretary (ICSI M. No: A52980), on behalf of Valiant Organics Limited.

Historical Stock Returns for Valiant Organics

1 Day5 Days1 Month6 Months1 Year5 Years
+0.98%+4.89%-4.62%+6.07%-37.83%-82.07%

How might the exercise price of Rs. 10 per option — set at face value and significantly below current market price — impact employee retention and the potential dilution effect on existing shareholders?

What performance criteria has Valiant Organics' NRC set for the remaining options beyond the 15,000 time-based vesting tranche, and how will achievement be measured?

Could this ESOP grant signal Valiant Organics' plans for expansion or talent acquisition in specific business segments, and what strategic initiatives might the company be preparing for?

Valiant Organics Posts ₹3,435.56 Lakh Net Profit in FY26, Publishes Results in Newspapers

3 min read     Updated on 18 May 2026, 07:51 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Valiant Organics Limited published its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, in newspapers on May 17, 2026, per Regulation 47 of SEBI LODR. The company reported a standalone net profit of ₹3,435.56 lakh against a net loss of ₹299.84 lakh in FY25, with total income rising to ₹74,529.79 lakh. On a consolidated basis, net profit after tax stood at ₹3,322.85 lakh, with net worth at ₹72,526.26 lakh.

powered bylight_fuzz_icon
40479522

*this image is generated using AI for illustrative purposes only.

Valiant Organics Limited published its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, in newspapers on Sunday, May 17, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were published in the Financial Express (English edition) and Mumbai Lakshadeep (Marathi edition). The company returned to profitability in FY26, recording a standalone net profit of ₹3,435.56 lakh compared to a net loss of ₹299.84 lakh in the previous fiscal year, supported by revenue from operations that increased to ₹73,838.31 lakh from ₹71,876.18 lakh in FY25.

Financial Performance

Total income for the year ended March 31, 2026, grew to ₹74,529.79 lakh from ₹72,701.54 lakh in the prior year. Total expenses decreased to ₹70,795.98 lakh from ₹72,460.55 lakh, while profit before tax improved substantially to ₹4,305.89 lakh from ₹240.99 lakh. The financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on Saturday, May 16, 2026. The statutory auditors, M/s. Gokhale & Sathe, issued an audit report with an un-modified opinion for the financial year ended March 31, 2026.

Standalone Financial Results

The table below summarises the key standalone financial metrics for the year ended March 31, 2026:

Particulars: Year Ended 31-Mar-2026 (₹ in Lakhs) Year Ended 31-Mar-2025 (₹ in Lakhs)
Revenue from Operations 73,838.31 71,876.18
Total Income 74,529.79 72,701.54
Total Expenses 70,795.98 72,460.55
Profit Before Tax 4,305.89 240.99
Net Profit / (Loss) 3,435.56 (299.84)
Basic EPS (₹) 12.27 (1.09)
Diluted EPS (₹) 12.26 (1.09)

For the quarter ended March 31, 2026, standalone net profit stood at ₹1,511.74 lakh, a significant rise from ₹395.62 lakh in the corresponding quarter of the previous year. Total income from operations for the quarter reached ₹22,170.99 lakh, up from ₹20,447.93 lakh in the same period last year.

Consolidated Financial Results

On a consolidated basis, total income from operations for the year ended March 31, 2026, stood at ₹74,567.86 lakh. Consolidated net profit after tax for the year was ₹3,322.85 lakh, compared to a net loss of ₹(299.84) lakh in the prior year on a standalone basis. Total comprehensive income on a consolidated basis for the year was ₹3,327.40 lakh. The consolidated net worth stood at ₹72,526.26 lakh, while reserves (excluding revaluation reserve) were ₹69,725.80 lakh.

Particulars: Quarter Ended 31-Mar-2026 Year Ended 31-Mar-2026
Total Income from Operations (₹ in Lakhs) 22,176.67 74,567.86
Net Profit After Tax (₹ in Lakhs) 1,571.92 3,322.85
Total Comprehensive Income (₹ in Lakhs) 1,583.87 3,327.40
Basic EPS (₹) 5.61 11.86
Diluted EPS (₹) 5.61 11.86
Net Worth (₹ in Lakhs) — 72,526.26

Segment Reporting

Based on internal reports, the Board approved the identification of the Pharma Business as an additional reportable segment alongside the existing Specialty Chemicals segment, in accordance with Ind AS 108. For the year ended March 31, 2026, the Specialty Chemical Division reported revenue of ₹57,481.94 lakh, while the newly identified Pharma Division reported revenue of ₹16,356.38 lakh. The company also received ₹852.76 lakhs towards a fire insurance claim settlement during the year, with ₹572.08 lakhs recognised under exceptional items. The full format of the audited financial results is available on the company's website at www.valiantorganics.com and on the BSE and NSE websites.

Historical Stock Returns for Valiant Organics

1 Day5 Days1 Month6 Months1 Year5 Years
+0.98%+4.89%-4.62%+6.07%-37.83%-82.07%

How might Valiant Organics plan to scale its newly identified Pharma Division, and what revenue contribution is it targeting relative to the Specialty Chemicals segment over the next 2-3 years?

Given the significant turnaround from a net loss to ₹3,435 lakh profit in FY26, what sustainability risks—such as raw material cost volatility or regulatory changes—could threaten this profitability trajectory in FY27?

Will the formal recognition of the Pharma Business as a separate reportable segment lead to dedicated capital allocation or potential demerger plans that could unlock shareholder value?

More News on Valiant Organics

1 Year Returns:-37.83%